Skip to main content

Table 4 Fasting blood glucose and insulin dose

From: Treatment satisfaction and quality-of-life between type 2 diabetes patients initiating long- vs. intermediate-acting basal insulin therapy in combination with oral hypoglycemic agents – a randomized, prospective, crossover, open clinical trial

  Baseline (Visit 2) End of period 1 End of period 2
FBG (before breakfast) in mmol/L, mean ± SD    
Sequence A 9.24 ± 2.23 6.48 ± 1.66 6.27 ± 1.32
Sequence B 9.50 ± 2.16 6.60 ± 1.82 6.15 ± 1.42
p-value*   0.55 0.46
Daily insulin doses in U, mean ± SD    
Sequence A 0 24.9 ± 20.3 28.7 ± 20.1
Sequence B 0 24.8 ± 15.7 26.0 ± 17.0
p-value*   0.96 0.21
Insulin doses by bodyweight in U/kg, mean ± SD    
Sequence A 0 0.27 ± 0.20 0.31 ± 0.21
Sequence B 0 0.27 ± 0.15 0.28 ± 0.16
p-value*   0.88 0.13
  1. Legend: * Unpaired t-test was applied for comparison of treatments in periods; Sequence A: starting with insulin glargine and then switching to NPH insulin; Sequence B: starting with NPH insulin and then switching to insulin glargine